Kelix bio Acquires DiabTec from Julphar
Deal News | Jan 16, 2025 | Zawya
Mubadala Investment Company's wholly owned unit, Kelix bio, has successfully acquired DiabTec, a subsidiary of the pharmaceutical company Julphar, enhancing Mubadala's presence in the life sciences sector in the MENA region and supporting the wider initiative to bolster local manufacturing in the UAE. The acquisition of DiabTec, a state-of-the-art facility with production capabilities built to EU/US FDA standards, is a strategic move by the sovereign investment arm of Abu Dhabi aimed at reinforcing the availability of essential biologicals such as insulin analogues. This transaction is a response to the increasing global demand for diabetes treatments and supports Mubadala's commitment to resolving crucial health care challenges while strengthening the UAE's role in the global biomanufacturing landscape. The divestment from Julphar aligns with its strategy to dispose of non-core assets while supporting Mubadala's agenda to advance pharmaceutical production and life sciences in the region.
Sectors
- Life Sciences & Pharmaceuticals
- Investment & Private Equity
Geography
- United Arab Emirates – The acquisition involves key entities based in the UAE, including Mubadala and Julphar, indicating a significant regional focus on life sciences and pharmaceutical growth.
- MENA Region – Kelix bio aims to establish biomanufacturing capabilities across the MENA, highlighting the geographical impact of the acquisition.
Industry
- Life Sciences & Pharmaceuticals – The article discusses the acquisition of DiabTec, a facility focused on biomanufacturing drug products, which strengthens the capabilities in the life sciences sector.
- Investment & Private Equity – Mubadala Investment Company, a sovereign investor, acquired a subsidiary for strategic growth and advancement in the life sciences sector.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Mubadala Investment Company | Acquiring Company | Company | A sovereign wealth fund of Abu Dhabi, driving strategic acquisitions in the life sciences sector. |
| Kelix bio | Acquiring Company/Subsidiary | Company | A Mubadala-owned entity focused on advancing the biomanufacturing landscape in the MENA region. |
| Julphar | Vendor | Company | A UAE-based pharmaceutical manufacturer divesting non-core assets to strengthen its focus on primary operations. |
| DiabTec | Target Company | Company | A subsidiary of Julphar specializing in biomanufacturing and drug products, now acquired by Kelix bio. |
| Sheikh Saqer Bin Humaid Al Qasimi | Chairman of the Board | Person | Chairman of Julphar overseeing strategic divestments. |
| Dr Bakheet Al Katheeri | Chief Executive Officer | Person | CEO of Mubadala's UAE Investments Platform, guiding strategic acquisitions in life sciences. |
| Ismail Ali Abdulla | Executive Director of UAE Clusters | Person | Executive at Mubadala involved in investment strategy and developments in life sciences. |
| Hocine Sidi Said | CEO | Person | CEO of Kelix bio, advocating for growth in the life sciences sector post-acquisition. |